{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:16:14Z","timestamp":1788441374935,"version":"build-2803163510"},"reference-count":33,"publisher":"IMR Press","issue":"8","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["2025JJ80711"],"award-info":[{"award-number":["2025JJ80711"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Leading talent project of Hunan Provincial People\u2019s Hospital","award":["20230327-1012"],"award-info":[{"award-number":["20230327-1012"]}]},{"name":"Scientific and Technological Innovation Team Project of Hunan Provincial People\u2019s Hospital","award":["KCTG202502"],"award-info":[{"award-number":["KCTG202502"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background:Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide. Gemcitabine (Gem) is a commonly used drug against HCC, but its efficacy is limited by the development of resistance. Resveratrol (Res), a natural polyphenol with antitumor activity, may reverse Gem resistance in HCC, although the mechanism remains unclear.Methods:The effects of Res on the proliferation, apoptosis, cell cycle, and invasion of Hep3B and HuH-7 cells were assessed via cell counting kit-8 (CCK-8), clonogenic, flow cytometry, and Transwell assays, respectively. Potential Res targets were predicted by network pharmacology, and markers of HCC prognosis were identified from the cancer genome atlas (TCGA) data. The interaction between Res and thymidylate synthase (TYMS) was validated by molecular docking and dynamics simulation. A Gem-resistant HuH-7 cell line (HuH-7\/GR) was established, and when these cells were treated with Res combined with Gem, the effect on Gem sensitivity was detected by CCK-8 assay, clonogenic assay, and flow cytometry. Finally, a subcutaneous nude mouse model of HCC was used to evaluate the in vivo effects of Res combined with Gem.Results:Res inhibited HCC cell proliferation, induced apoptosis and G2\/M arrest, and suppressed invasion in a concentration-dependent manner. Network pharmacology and TCGA analysis identified TYMS as an important target gene for Res. TYMS was highly expressed in HCC tissues and correlated with poor prognosis. Res treatment reduced TYMS expression, while molecular docking and simulation showed stable binding of Res to TYMS. TYMS levels were elevated in HuH-7\/GR resistant cells. Res combined with Gem was found to reverse drug resistance, inhibit proliferation and colony formation, and induce apoptosis. The Res + Gem combination group showed the smallest tumor volume in the in vivo model.Conclusion:By attenuating Gem resistance through TYMS inhibition, Res holds promise as a clinically viable adjunct to Gem-based chemotherapy, offering a potential strategy to improve outcomes in HCC patients.<\/jats:p>","DOI":"10.31083\/fbl52448","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:35:31Z","timestamp":1788438931000},"source":"Crossref","is-referenced-by-count":0,"title":["Resveratrol Attenuates Gemcitabine Resistance in Hepatocellular Carcinoma Cells by Inhibiting Thymidylate Synthase"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6241-350X","authenticated-orcid":true,"given":"You","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, Hunan Provincial People\u2019s Hospital, The First Affiliated Hospital of Hunan Normal University, 410005 Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-1737","authenticated-orcid":true,"given":"Chuang","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Hunan Provincial People\u2019s Hospital, The First Affiliated Hospital of Hunan Normal University, 410005 Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-3922","authenticated-orcid":true,"given":"Sulai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Hunan Provincial People\u2019s Hospital, The First Affiliated Hospital of Hunan Normal University, 410005 Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5996-927X","authenticated-orcid":true,"given":"Yunfeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Hunan Provincial People\u2019s Hospital, The First Affiliated Hospital of Hunan Normal University, 410005 Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2192-4816","authenticated-orcid":true,"given":"Siwei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Hunan Provincial People\u2019s Hospital, The First Affiliated Hospital of Hunan Normal University, 410005 Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0834-9469","authenticated-orcid":true,"given":"Ya","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, 650000 Kunming, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7318-5910","authenticated-orcid":true,"given":"Zhiguo","family":"Tan","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University, 730000 Lanzhou, Gansu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-5043","authenticated-orcid":true,"given":"Xu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Hunan Provincial People\u2019s Hospital, The First Affiliated Hospital of Hunan Normal University, 410005 Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5308-1447","authenticated-orcid":true,"given":"Ou","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Hunan Provincial People\u2019s Hospital, The First Affiliated Hospital of Hunan Normal University, 410005 Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Aparicio B, Silva L, Ruiz M, Ll\u00f3piz D, Rep\u00e1raz D, Theunissen P, et al. Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy. Oncoimmunology. 2026; 15: 2645280.","DOI":"10.1080\/2162402X.2026.2645280"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Gkatzionis A, Sanderson E, Smith GD, Stender S, Gellert-Kristensen H. Disentangling the Effect of BMI on Hepatocellular Carcinoma From Cirrhosis With Multivariable Mendelian Randomization. Liver International : Official Journal of the International Association for the Study of the Liver. 2026; 46: e70609.","DOI":"10.1111\/liv.70609"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Lei YR, He XL, Li K, Mo S. Drug resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Frontiers in Bioscience (Landmark Edition). 2024; 29: 52.","DOI":"10.31083\/j.fbl2902052"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Wu Y, Ju G, Zhou X, Wu J, Zheng S, Peng C. Targeting WTAP sensitizes hepatocellular carcinoma to sorafenib by inhibiting the ERK signaling pathway. Journal of Zhejiang University. Science. B. 2026; 27: 310\u2013320.","DOI":"10.1631\/jzus.B2500191"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer. 2007; 109: 1384\u20131390.","DOI":"10.1002\/cncr.22532"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Li N, Hu B, Liu C, Du K, Guo B, Yan M, et al. Targeting FUT1-mediated EGFR fucosylation and COX-2 reverses gemcitabine resistance by activating immunogenic cell death in hepatocellular carcinoma. Bioorganic Chemistry. 2025; 166: 109111.","DOI":"10.1016\/j.bioorg.2025.109111"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Sayed AE, Gomes N, Zakrzewski M, Liudkovska V, Serwa R, Azzi A. The mTORC2 component SIN1 post-transcriptionally regulates TYMS levels and modulates P53 activity in response to 5-FU chemotherapy. Cell Communication and Signaling : CCS. 2026; 24: 111.","DOI":"10.1186\/s12964-025-02640-y"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Vijayakurup V, Meyer B, Rizvi SR, Kievit KH, Hyder I, Koh J, et al. Integrated proteomic analysis identifies TYMS-dependent AMPK-mTOR signaling in pancreatic neuroendocrine tumors. iscience. 2025; 28: 113833.","DOI":"10.1016\/j.isci.2025.113833"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Zhang X, Shi L, Gao Y, Zhou C, Wang X, Shi X. Chidamide enhances the sensitivity of gastric cancer to 5-fluorouracil chemotherapy by suppressing the HDAC3\/HNF4A\/TYMS axis. Cell Death & Disease. 2025; 17: 2.","DOI":"10.1038\/s41419-025-08247-y"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, et al. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Investigational New Drugs. 2011; 29: 1057\u20131065.","DOI":"10.1007\/s10637-010-9413-7"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Chu CS, Chen HP, Lin PH, Cheng CC, Kuo HY, Fan PH, et al. Interleukin-1 receptor 1 deficiency worsens hepatocellular carcinoma, while gemcitabine treatment alleviates the hepatocellular carcinoma-induced increase in intra-hepatic immune cells. Journal of Gastroenterology and Hepatology. 2024; 39: 2208\u20132218.","DOI":"10.1111\/jgh.16674"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Dorman SN, Baranova K, Knoll JHM, Urquhart BL, Mariani G, Carcangiu ML, et al. Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning. Molecular Oncology. 2016; 10: 85\u2013100.","DOI":"10.1016\/j.molonc.2015.07.006"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Li S, Zhao J, Lv L, Dong D. Identification and Validation of TYMS as a Potential Biomarker for Risk of Metastasis Development in Hepatocellular Carcinoma. Frontiers in Oncology. 2021; 11: 762821.","DOI":"10.3389\/fonc.2021.762821"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Abdel Allah HMM, Zahran WE, El-Masry SA, El-Bendary M, Soliman AF. Association of MTHFR and TYMS gene polymorphisms with the susceptibility to HCC in Egyptian HCV cirrhotic patients. Clinical and Experimental Medicine. 2022; 22: 257\u2013267.","DOI":"10.1007\/s10238-021-00747-3"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Jiang Z, Li Y. CD93-targeted resveratrol-loaded PLGA nanoparticles remodel CD8+ T cell metabolism through AIF-mediated oxidative phosphorylation to overcome lung cancer immunotherapy resistance. Journal of Nanobiotechnology. 2026; 24: 382.","DOI":"10.1186\/s12951-026-04216-5"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Wang G, Yuan Y, Tang Y, Ma Q, Jiang H. Resveratrol inhibits pancreatic cancer progression via the ING5 signaling pathway. Scientific Reports. 2026; 16: 13473.","DOI":"10.1038\/s41598-026-44216-x"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Zhang L, Zeng Q, Kang Z, Fang S, Huang T, Pohla H, et al. Investigation of the impact of resveratrol on sublethal-dose ALA-PDT in glioblastoma cells. Photochemical & Photobiological Sciences : Official Journal of the European Photochemistry Association and the European Society for Photobiology. 2026; 25: 697\u2013709.","DOI":"10.1007\/s43630-026-00877-1"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Hedayati N, Safari MH, Milasi YE, Kahkesh S, Farahani N, Khoshnazar SM, et al. Modulation of the PI3K\/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity. Discover Oncology. 2025; 16: 669.","DOI":"10.1007\/s12672-025-02471-w"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Zhang M, Yuan W, Li C, Chen C, Liu X, Ma Z, et al. Resveratrol and N-acetylcystein reduce hepatic steatosis but enhance initiation and progression of hepatocellular carcinoma by inhibiting GST-pi-MAPK axis in mice. Frontiers in Pharmacology. 2025; 16: 1574039.","DOI":"10.3389\/fphar.2025.1574039"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Molecular Cancer Therapeutics. 2005; 4: 1465\u20131474.","DOI":"10.1158\/1535-7163.MCT-05-0198"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Liu Z, Peng Q, Li Y, Gao Y. Resveratrol enhances cisplatin-induced apoptosis in human hepatoma cells via glutamine metabolism inhibition. BMB Reports. 2018; 51: 474\u2013479.","DOI":"10.5483\/BMBRep.2018.51.9.114"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Lin J, Schyschka L, M\u00fchl-Benninghaus R, Neumann J, Hao L, Nussler N, et al. Comparative analysis of phase I and II enzyme activities in 5 hepatic cell lines identifies Huh-7 and HCC-T cells with the highest potential to study drug metabolism. Archives of Toxicology. 2012; 86: 87\u201395.","DOI":"10.1007\/s00204-011-0733-y"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Zhou Q, Li Y, Li X, Zhang S, Wang Y, Li Z, et al. Pleckstrin-2 promotes the progression of colorectal cancer via YTHDF2-mediated TYMS mRNA stability. Cellular and Molecular Life Sciences : CMLS. 2025; 82: 284.","DOI":"10.1007\/s00018-025-05782-x"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Ligabue A, Marverti G, Liebl U, Myllykallio H. Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression. PloS One. 2012; 7: e47318.","DOI":"10.1371\/journal.pone.0047318"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Yang A, Wu Q, Chen Q, Yang J, Li H, Tao Y, et al. Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase. Chemico-biological Interactions. 2022; 360: 109938.","DOI":"10.1016\/j.cbi.2022.109938"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Guo A, Chang Y, Lin J, Guo J, He Y, Wang C, et al. Resveratrol Enhances Anticancer Effects of Silybin on HepG2 Cells and H22 Tumor-bearing Mice via Inducing G2\/M Phase Arrest and Increasing Bax\/Bcl-2 Ratio. Combinatorial Chemistry & High Throughput Screening. 2025; 28: 89\u201398.","DOI":"10.2174\/0113862073263408231101105647"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Wang L, Shi C, Yu J, Xu Y. FOXM1-induced TYMS upregulation promotes the progression of hepatocellular carcinoma. Cancer Cell International. 2022; 22: 47.","DOI":"10.1186\/s12935-021-02372-2"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Zhou W, Xiao Y, Jiang Y, Zou A, Ruan J, Feng X, et al. Association of MTHFR rs9651118 and TYMS rs2790 Polymorphisms with Risk of Cancers: A Case-Control Study and Meta-analysis. Biochemical Genetics. 2025; 63: 4037\u20134056.","DOI":"10.1007\/s10528-024-10929-9"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol. 2014;11:282\u2013298.","DOI":"10.1038\/nrclinonc.2014.51"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Wu Q, Chen Q, Yang J, Zhang J, Yang A. Material basis revelation of anti-hepatoma effect of Huachansu (Cinobufacini) through down-regulation of thymidylate synthase. Chinese Herbal Medicines. 2024; 17: 127\u2013138.","DOI":"10.1016\/j.chmed.2024.04.002"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Chen A, Yin K, Cui Q, Liu Y, Wan X, Yang W. Preventing liver carcinogenesis through the use of inhibitors targeting metabolic enzymes ACLY, G6PD, and TYMS, combined with 9-cis retinoic acid. International Journal of Biological Macromolecules. 2025; 331: 148378.","DOI":"10.1016\/j.ijbiomac.2025.148378"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Karim A, Khan HA, Ahmad F, Qaisar R. Improvement in postural imbalance with intake of resveratrol (polyphenolic phytoalexin) in patients of knee osteoarthritis. Explore (New York, N.Y.). 2026; 22: 103341.","DOI":"10.1016\/j.explore.2026.103341"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Karim A, Khan HA, Ahmad F, Qaisar R. Resveratrol supplementation improves functional performance in knee osteoarthritis by upregulating sirtuin 1: a randomized study. Inflammopharmacology. 2025; 33: 6877\u20136886.","DOI":"10.1007\/s10787-025-01967-9"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/8\/10.31083\/FBL52448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:35:37Z","timestamp":1788438937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/8\/10.31083\/FBL52448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)02215-X"],"URL":"https:\/\/doi.org\/10.31083\/fbl52448","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"52448"}}